Key result
Mesalazine triggers acute myocarditis in a young patient, resolving rapidly upon drug discontinuation.
Why the study?
Myocarditis is a rare complication of inflammatory bowel disease and mesalazine-induced myocarditis is uncommon and not well characterized.
Case Report (n=1)
No
Mesalazine can induce acute myocarditis in patients with ulcerative colitis, which is reversible upon discontinuation of the drug.
Answers are grounded in this paper and cite their sources.
Clinicians should consider mesalazine-induced myocarditis in UC; Level 5 case report leaves open incidence and causality.
Mesalazine is a commonly used first-line therapy to treat acute mild to moderate ulcerative colitis (UC). Myocarditis is a rare complication of inflammatory bowel disease. This is a case report of a 19-year-old female with myocarditis induced after commencing mesalazine for UC. She was admitted with pleuritic-type chest pain associated with severe dyspnoea and was hemodynamically unstable during admission. She had elevated troponin and N-terminal pro-B-type natriuretic peptide. Transthoracic echocardiogram (TTE) results suggested there was evidence of myocarditis with reduced ejection fraction, which was later confirmed by cardiac magnetic resonance imaging. There was a rapid improvement of cardiac status after stopping mesalazine within two weeks.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2021) conducted a case report in Ulcerative Colitis (n=1). Mesalazine was evaluated on Development of acute myocarditis. A 19-year-old female with ulcerative colitis developed acute myocarditis four weeks after starting mesalazine, which rapidly resolved upon discontinuation of the drug.
Synapse has enriched 10 related papers. Consider them for comparative context: